skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Current and novel antibiotics against resistant Gram-positive bacteria

Review

(4923) Views  (2487) Full article downloads

Authors: Federico Perez, Robert A Salata, Robert A Bonomo

Published Date September 2008 Volume 2008:1 Pages 27 - 44
DOI: http://dx.doi.org/10.2147/IDR.S3545

Federico Perez1, Robert A Salata1, Robert A Bonomo2

1Division of Infectious Diseases and HIV Medicine, University Hospitals Case Medical Center, Cleveland OH, USA; 2Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA

Abstract: The challenge posed by resistance among Gram-positive bacteria, epitomized by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE) and vancomycin-intermediate and -resistant S. aureus (VISA and VRSA) is being met by a new generation of antimicrobials. This review focuses on the new β-lactams with activity against MRSA (ceftobiprole and ceftaroline) and on the new glycopeptides (oritavancin, dalbavancin, and telavancin). It will also consider the role of vancomycin in an era of existing alternatives such as linezolid, daptomycin and tigecycline. Finally, compounds in early development are described, such as iclaprim, friulimicin, and retapamulin, among others.

Keywords: Gram-positive bacteria, vancomycin, anti-MRSA cephalosporins, lipoglycopeptides, daptomycin, linezolid, tigecycline








Readers of this article also read:

Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Morgellons disease: Analysis of a population with clinically confirmed microscopic subcutaneous fibers of unknown etiology
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Lyme disease: the next decade
Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University